American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter dema🧸nd for its cancer drugs.

AstraZeneca reported quarterly core 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) of $2.06, with revenue advancing 16.5% to $12.68 billion. Both were more than estimates.

The company said sales of oncology treatments increased 23% to $5.11 billion, with gains across all key medicines and regions. Cardiovascular, renal, 🍸and metabolism drug revenue added 20% to $3.06 billion, driven by a 43% jump in saleꦦs of its Farxiga diabetes treatment.

Revenue from medicines made in partner🌳ship with other companies soared 59%꧅ to $457 million.

澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) Pascal Soriot explained that AstraZeneca’s “strong pipeline momentum continued,” adding that it has already announced po𒈔sitive trial results for its lung cancer medicines Imfinzi and Tagrisso.

AstraZeneca ADRs were up 5.6% to $75.20 as of noon ET and have gained nearly 12% so far this year. They reached their all-time high of $76.56 precisely one year ago.